Table 5. Sensitivity, specificity, AUC, positive predictive value (PPV) and negative predictive value (NPV) of CMV34 and other clinical parameters associated to postnatal outcome.
| Sensitivity (% [95% CI]) | Specificity (% [95% CI]) | AUC [95% CI] | PPV* (% [95% CI]) | NPV* (% [95% CI]) | |
|---|---|---|---|---|---|
| CMV34 ° | 89 [51.8–99.7] | 75 [42.8–94.5] | 0.90 [0.68–0.98] | 0.35 [0.03–0.85] | 0.98 [0.62–1.00] |
| CMV DNA levels in amniotic fluid °° | 79 [54.4–93.9] | 84 [63.9–95.5] | 0.84 [0.70–0.93] | 0.42 [0.05–0.88] | 0.96 [0.72–1.00] |
| CMV DNA levels in fetal blood °° | 92 [64.0–99.8] | 59 [36.4–79.3] | 0.81 [0.65–0.92] | 0.25 [0.02–0.71] | 0.98 [0.55–1.00] |
| Fetal platelet count °° | 82 [48.2–97.7] | 70 [45.7–88.1] | 0.77 [0.58–0.90] | 0.29 [0.01–0.83] | 0.96 [0.54–1.00] |
° Data given for validation cohort only.
°° Data given for both discovery and validation cohort since missing values did not allow a separate analysis of the discovery and validation cohort.
* Based on a prevalence of 13% [1] of symptomatic CMV infected individuals; confidence intervals were calculated using variable numbers of cases: 22 for CMV34; 19 for CMV DNA levels in amniotic fluid, 13 for CMV DNA levels in fetal blood and 11 for fetal platelet count.